Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingMETXF 14 EV-to-EBITDA is -44.63 as of Aug. 26, 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 413 Biotechnology companies, ME Therapeutics Holding ranks worse than 242130.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ME Therapeutics Holding's enterprise value is $40.88 Mil.
ME Therapeutics Holding's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was $-0.92 Mil. Therefore, ME Therapeutics Holding's EV-to-EBITDA for today is -44.63.
The historical rank and industry rank for ME Therapeutics Holding's EV-to-EBITDA or its related term are showing as below:
METXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -44.77 Med: 0 Max: 0
Current: -44.77
METXF's EV-to-EBITDA is ranked worse than 100% of 413
companies
in the Biotechnology industry
Industry Median: 13.87
vs METXF: -44.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ME Therapeutics Holding (OTCPK:METXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ME Therapeutics Holding's PE Ratio (TTM) for today is calculated as:
ME Therapeutics Holding's share price for today is $3.25.
ME Therapeutics Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
METXF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's EV-to-EBITDA falls into.
ME Therapeutics Holding's current Enterprise Value is $40.88 Mil.
ME Therapeutics Holding's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (METXF) has a EV-to-EBITDA of -44.63 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ME Therapeutics Holding. According to the industry distribution chart, ME Therapeutics Holding ranks #999999 out of 413 companies in the Biotechnology industry.
Is ME Therapeutics Holding's EV-to-EBITDA too high?
ME Therapeutics Holding's current EV-to-EBITDA is -44.63. Based on the distribution chart, ME Therapeutics Holding ranks #999999 out of 413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #999999 out of 413 companies for EV-to-EBITDA. This places ME Therapeutics Holding in the lower half of its industry. The industry median EV-to-EBITDA is 13.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.87, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ME Therapeutics Holding. For the Biotechnology industry, the median EV-to-EBITDA is 13.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ME Therapeutics Holding's current EV-to-EBITDA is -44.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current EV-to-EBITDA of -44.63. The current EV-to-EBITDA is -44.63. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current EV-to-EBITDA is -44.63 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for METXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
METXF has been successfully added to your 
